Good day, ladies and gentlemen, and welcome to the Teleflex First Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen only mode. Later, there will be a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Jake L.
Guise, Treasurer and Vice President of Investor Relations. Sir, you may begin.
Thank you, operator, and good morning, everyone, and welcome to the Teleflex Incorporated Q1 2018 earnings conference call. The press release and slides to accompany this call are available on our website at www.teleplex.com. As a reminder, this call will be available on our website and a replay will be available by dialing 855-859-2056 or for international calls, 404-537-3406, passcode 269,000,000 Participating on today's call are Liam Kelly, President and Chief Executive Officer and Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom will provide prepared remarks, and then we'll open up the call to Q and A. Before we begin, I'd like to remind you that some of the matters discussed in the conference call will contain forward looking statements regarding future events as outlined in our slides.
We wish to caution you that such statements are, in fact, forward looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include, but are not limited to, factors referenced in our press release today as well as our filings with the SEC, including our Form 10 ks, which can be accessed on our website. With that, I'd like to turn the call over to Liam.
Thank you, Jake, and good morning, everyone. It is a pleasure to once again have an opportunity to speak with the investment community regarding Teleflex, and I am pleased to report that we are off to a solid start in 2018. The results achieved in quarter 1, along with our projections for the remainder of the year, allow us to reaffirm many of our previously provided financial guidance metrics, while also affording us an opportunity to increase a couple of others, including our full year adjusted earnings per share range. And while Tom will go into more details on our full year EPS guidance range, I would like to take a moment to discuss our full year revenue guidance. We are pleased to reaffirm our full year constant currency revenue guidance range of between 12% 13%, as well as our full year organic constant currency revenue growth range of between 5% 5.5%.
I remain confident in our ability to achieve both of these ranges based on the anniversary of the surgical product line exit combined with the easier European comparable in the second half of the year, as well as the NeoTract acquisition being counted as organic revenue in the 4th I'm also pleased to say that due to the favorable FX environment, we are raising our as reported revenue growth guidance by 1% on both the low and high end of the range. I would also like to point out that we expect the percentage of revenue generated in quarters 2 and 3 to mirror the quarterly percentages achieved in 2017 when we achieved approximately 25% in both quarter 2 and quarter 3 with the remainder generated in quarter 4. Turning now to the Q1 and beginning with revenue. During quarter 1, we generated as reported revenue growth of approximately 20% and constant currency revenue growth of approximately 15%. The constant currency revenue growth increase was broad based and represents a mixture of both improvements in the company's organic growth rates as well as the contributions received from the acquisitions of NeoTract and Vascular Solutions.
Starting with the organic revenue growth drivers. During quarter 1, we saw recovery in distributor purchasing patterns that negatively impacted us during the Q4 of 2017. You may recall that on our last earnings call, we stated that distributor buying can at times be uneven and that we expected inventory levels held at certain U. S.-based distributors to normalize during the first half of the year. Well, that is what happened in quarter 1 and this helped accelerate our organic shipping day adjusted constant currency revenue growth rate to 3.1%.
Other areas in which we saw good organic revenue growth were in the segments of Interventional North America, Vascular North America and Asia Pacific. One segment, however, that experienced a decline in constant currency revenue growth was our Surgical business, and this was largely attributable to our exit of certain low growth, low margin products beginning in the Q3 of 2017. Had we remained in these categories and revenue simply remained flat versus the year ago period, our organic revenue growth would have been higher by approximately 60 basis points. That said, we know that our exit from these products will have a positive long term effect on our business. Turning to M and A, NeoTract continued its strong momentum as global revenue during the quarter totaled $42,300,000 which is an increase of approximately 87% versus the prior year period.
We continue to see an increase in the adoption of the UroLift product and we also continue to expand the number of covered lives from an insurance perspective as we are now up to approximately 240,000,000 thanks to the positive position issued recently by the Blue Cross Blue Shield Association. And lastly, as it relates to NeoTract, we recently published the results from a retrospective study, which confirms the clinical results from our previously published 5 year LIFT study. Moving to Vascular Solutions. During quarter 1, revenues reached $47,700,000 It is important to understand that we completed this acquisition in mid February of last year. And as such, only half a quarter of BSI revenue appeared within Teleflex's financial statements during the Q1 of 2017.
If you were to compare the full 3 months of BSI revenue from the Q1 of 2017 to the Q1 of 2018, BSI revenue increased approximately 10% on a shipping day adjusted basis. In addition to generating good year over year growth, BSI revenue growth performance in the quarter was also an improvement on a sequential basis. As a reference point, assuming our quarter one results included a full 3 months of organic growth for both NeoTract and Vascular Solutions, then our pro form a quarter 1 2018 organic growth adjusted for shipping days would have been approximately 6.6%. This clearly shows the power that both vascular solutions and NeoTract can have on Teleflex's organic constant currency revenue growth rate going forward. In addition to getting off in the right direction to begin the year from a revenue perspective, we also continue to deliver solid margin and adjusted earnings per share expansion in the quarter.
As we increased our adjusted gross margin by about 190 basis points, our adjusted operating margin by 60 basis points and our adjusted earnings per share by 19.4%. Finally, we recently initiated a new restructuring program, which should allow us to continue to drive non revenue dependent margin expansion in the future. With that as an overview, let's now look at quarter on results in a bit more detail. 1st quarter 2018 revenue totaled 587 point $2,000,000 and increased 14.6 percent on a constant currency basis. Beginning with the components of organic revenue growth, During quarter 1, we saw organic constant currency revenue growth of 1.8%.
We had 1 fewer shipping day in the Q1 of 2018 and this caused a headwind to revenue growth of approximately 1.3%. So on a day adjusted basis, we estimate our organic constant currency revenue growth was approximately 3.1%. This day adjusted organic growth consisted of 1.6% from legacy product volumes, 1.5% from new products and positive pricing adding about 60 basis points. These positive contributors to day adjusted organic constant currency growth were partially offset by the surgical product exit, which negatively impacted quarter 1 growth by about 60 basis points. Moving to the contribution we received from acquisitions.
NeoTract added 8.3 percent, vascular solutions added 4.2% and other M and A added another 30 basis points to our constant currency growth for the quarter. Next, I would like to provide some additional details surrounding our segment and product related constant currency revenue growth drivers. Vascular North America 1st quarter revenue increased 4.9% on a constant currency basis to $83,000,000 When normalizing for the shipping day impact, we estimate that vascular revenues would have increased by 6.5%. The increase in vascular constant currency revenues was all organic and was due to an increase in new product sales and higher sales volume of existing products during the quarter. During the quarter, PIK revenues were particularly strong, growing approximately 20% versus the Q1 of 2017.
Moving to Interventional North America. 1st quarter revenue was $60,200,000 which is an increase of approximately 50.6 percent on a constant currency basis. The increase is primarily the result of the addition of Vascular Solutions. When normalizing for the impact of M and A and shipping days, we estimate the organic revenue growth within our Interventional segment would have been 8%. Turning to Anesthesia North America.
1st quarter revenue was $50,600,000 which is an increase of 4.7% on a constant currency basis versus the prior year period. When normalizing for
the impact of M and A
and shipping days, we estimate that organic revenue growth within our anesthesia segment would have been 4.4%. The improvement in anesthesia revenue was due to an increase in new product sales and higher sales volume of existing products. Shifting to our Surgical North America business, its revenue decreased 11.7% on a constant currency basis to $40,700,000 When normalizing for the shipping day impact, we estimate that surgical revenues would have declined 10.2%. The decrease in surgical revenues was primarily due to our exit of a lower margin product line in the Q3 of 2017 that I referenced earlier. As we look forward into the remainder of 2018, we expect that our surgical business will continue to report negative constant currency revenue growth for the Q2 of the year because of the difficult comparison.
However, comps eased in the second half of twenty eighteen, thereby allowing for modest positive constant currency revenue growth in the second half of the year. Moving to our overseas operations. 1st quarter EMEA revenues were up 4.6 percent on a constant currency basis to $159,900,000 Within this growth rate, M and A contributed approximately 2.3%. When normalizing for
the impact of M and
A and shipping days, we estimate that organic revenue growth within this segment would have been 3.2%. Turning to Asia. Our first quarter revenue increased 9.1% on a constant currency basis to $58,200,000 Within this growth rate, M and A contributed approximately 3.5%. When normalizing for the impact of M and A, organic revenue growth within this segment was 5.6%. Shipping days did not have any impact on this segment.
Organic growth in this segment was led by China, whose revenues expanded 26%. This was largely driven by an increase in volume following our decision to take our business direct last year. Next, I'd like to brief you on our OEM segment. During the Q1, revenue was up approximately 2.9% on a constant currency basis and reached $45,800,000 When normalizing for the shipping day impact, we estimate that the increase in OEM revenues would have been 3.3%. The increase in OEM revenues was all organic and was due to higher sales volumes of existing products.
And lastly, 1st quarter revenues for the businesses within our all other category was up 85% on a constant currency basis, totaling $88,800,000 Growth here is primarily attributable to the acquisition of NeoTract and to a lesser extent respiratory product sales, which grew approximately 3.6%. That completes my comments on our segment revenue performance. I would now like to briefly update you on the status of GPO and IDN awards as well as some recent clinical announcements. Beginning with GPO and IDN, During the Q1, we won an additional 9 new GPO and IDN agreements and extended 6 others. Of the agreements won and extended in quarter 1, 6 were sole source in nature and covered a wide variety of clinical areas, including our CBC catheters, laryngeal masks, laryngoscopes, pain pumps and humidification product offering.
We are encouraged by our continued success in this area and it reinforces our view of the sustainability of our revenue generation. Next, I would like to provide you an update on 2 clinical studies that were recently published as well as an update on replas. The first clinical study involves NeoTract, and it is our belief that the data from this study further supports our thoughts that the UroLift system continues to prove itself as the new standard of care for men with enlarged prostate. On May 19, we announced the results from the first analysis of a retrospective registry of more than 800 UroLift System procedures performed at 7 centers in North America, Europe and Australia. The study found that the UroLift system offers significant improvement in symptoms and quality of life through 24 months among patients in the real world non clinical setting.
With a 40% reduction in IPSS score at 24 months, results were consistent with the data from the randomized 5 year LIFT study, which showed a highly tolerable, minimally invasive procedural experience, rapid reduction of symptoms after the procedure and sustained improvement in quality of life scores, iPSS and peak urinary flow rate while preserving sexual function. Additionally, the registry included patients in urinary retention who required a catheter to urinate prior to treatment. Of those with follow-up data, 96 percent could urinate without the use of a catheter within the 1st month following the UroLift procedure. The ability to get men in retention on the catheter is a big milestone in urology. We anticipate that the registry will continue to enroll additional sites and it is expected to increase to more than 2,000 patients.
The second study that I would like to talk to you about this morning involves the LMA Gastro. In the February edition of the British Journal of Anesthesia, the LMA Gastro Airway with Cuspilot technology was affirmed to yield a high airway insertion success rate and endoscopy success rate when using in patients undergoing an endoscopic procedure. The prospective study, which involved 292 patients, sought to determine the efficacy of the LMA gastro in patients undergoing upper endoscopy and concluded that the endoscope and LMA gastro insertion to
the
to the 2,009 study, more than 6,900,000 upper endoscopies are performed in the U. S. Each year and the use of moderate to deep sedation during endoscopy is a common practice. Respiratory depression from sedative drugs and airway obstruction requiring intervention are known risks associated with these procedures, with studies demonstrating that in 11% to 50% of cases, patients can become hypoxic. Today, many of these procedures are undertaken without an airway management device in place.
The LMA Gastro is the 1st laryngeal mask specifically designed to enable clinicians to proactively manage their patients' airways by facilitating direct endoscopic access via the integrated channel. We continue to see an increase in the adoption of this product globally and we anticipate the findings of this independent study will further aid in the adoption of this product moving forward. Next, I would like to provide you with a brief update on REPLAZ. As you may recall, in December of 2017, the FDA and the Department of Defense launched a joint program to expedite the approval of medical products that are intended to save lives in the U. S.
Military, including freeze dried plasma. Members of our Vascular Solutions Biologics Group had a meeting with the FDA in early January, and the FDA confirmed an accelerated biologics license application approval pathway and confirms that an efficacy study must be ongoing at the time of the licensure. Following this initial meeting, we met again with the FDA in early April. Like the first meeting, the most recent discussions went well and provided our team an opportunity to inform the FDA about our manufacturing process and validation plan. Following the meeting, there are no changes to our anticipated timeline for reclass and we continue to expect a BLA submission in early 2019.
And before I turn the call over to Tom, I'd like to share some details with you regarding another restructuring plan that was recently approved. Over the past several months, we have been evaluating opportunities to further improve our operating leverage and the plan we announced today is designed to further enhance our competitive position. These types of announcements are never easy and we only make these decisions after very careful consideration. It is our intention to speak with affected employees shortly. I realize that this may be an unsettling time for Teleflex employees as they hear the news of a new restructuring program.
And I would like to take a moment to thank all of the affected employees for their hard work and dedication and to share my commitment that we will treat you in a fair manner as we move through this process. Like previous plans, our new effort is focused on the relocation of certain manufacturing operations to an existing lower cost location, the outsourcing of certain distribution operations and related workforce reductions at certain of the company's facilities. Importantly, this is not something that will happen overnight. Rather, we expect certain actions to commence in the Q2 of this year and that these actions will be substantially completed by the end of 2024. From a financial standpoint, we estimate that we will incur aggregate pre tax restructuring and restructuring related charges in connection with the plan of between $102,000,000 $133,000,000 of which between $55,000,000 $72,000,000 will be incurred in 2018.
We currently expect that this plan will achieve annualized savings of between $25,000,000 $30,000,000 once it is fully implemented and that we will start realizing some very minor savings beginning in 2018. Given that we have not yet had an opportunity to speak with the impacted individuals and sites, we will not be going into more specifics at this time. That takes me to the end of my prepared remarks. Now I would like to turn the call over to Tom for a review of our financial results for the Q1 and our updated financial guidance for 2018. Tom?
Thanks, Liam, and good morning, everyone. Given the previous discussion of the company's revenue performance, I'll begin at the gross profit line. For the quarter, adjusted gross profit was 332,600,000 dollars versus $267,100,000 in the prior year quarter or an increase of 24.5%. Adjusted gross margin was 56.6 percent, a 190 basis point increase when compared to the prior year period. The expansion in adjusted gross margin reflects the impacts of the acquisitions of VASCO Solutions and NeoTract, favorable fluctuations in foreign currency exchange rates and the favorable impact of cost improvement initiatives.
Adjusted operating margin improved 60 basis points to 24%. The improvement was related to the gross margin flow through. However, this was partially offset by the inclusion of NeoTract, which currently operates at a higher OpEx cost structure. Adjusted net interest expense increased to $25,700,000 versus $15,100,000 in the prior year quarter. The increase reflects the impact of additional borrowings required to finance the acquisitions of Vasco Solutions and NeoTract.
Turning to the adjusted tax rate. For the quarter, it was 12.8% versus 16.1% in the prior year period. The year over year decline is due to a larger tax windfall benefit this year versus last year and the impact of the recently enacted Tax Cuts and Jobs Act. Moving to the bottom line, 1st quarter adjusted earnings per share increased by 19.4% to $2.15 So clearly, 1st quarter adjusted EPS outperformed our prior expectation. The favorable result is attributed to the following factors.
First, favorable exchange rates resulted in upside to revenue that flowed through to a modest EPS upside. 2nd, during the quarter, the tax windfall benefit from share based compensation was favorable versus our original 2018 budget assumption. 3rd, we had favorable OpEx spending in the Q1. The favorability was in part due to better expense control and in part due to a re phasing of expense timing. Our 2018 operating margin guidance of 26.1 percent to 26.5 percent had assumed a level of full year spending and we still expect that level of spending.
However, the timing will play out a little bit differently versus our original expectation. Additionally, given the strong Q1 earnings results, we now intend to spend a little bit more in OpEx on a full year basis to accelerate future top line growth. The additional spending would be to fund accelerated regulatory approval of RePlas following the favorable meeting with the FDA and to accelerate the timeline for UroLift regulatory filings in Asia and to accelerate sales force hiring plans for NeoTract in the U. S. Overall, if you exclude the favorable benefits from exchange rates, taxes and expense timing, Q1 results were largely in line with our internal operational expectations.
Turning now to select balance sheet and cash flow highlights. During the Q1, cash flow from operations totaled $7,000,000 down approximately 4% over the prior year period. The decrease was primarily due to changes in working capital. Then finally, during the quarter, our gross debt balance declined by approximately 18,500,000 dollars reflecting modest term loan repayments, while leverage for our credit facility definition stood at 3.4 times. That completes my comments on the Q1.
Now I'll move to 2018 guidance updates. Beginning with revenue, for 2018, we are reaffirming our full year constant currency revenue growth guidance range of between 12% 13%. And we continue to expect our organic revenue growth will be between 5% 5.5%. However, because of an improved outlook for foreign currency environment, we are raising our as reported revenue growth guidance from a range of between 14% 15% to a new range of between 15% 16%. Based on our updated currency assumptions, this translates to an as reported revenue range of between 2,468,000,000 dollars 2,490,000,000 We are also reaffirming both our previously provided adjusted gross margin guidance range of 50 7.5% to 58% and our adjusted operating margin guidance range of 26.1% to 26.5%.
Our full year 2018 adjusted tax rate guidance range remains 15% to 16%, although we now expect to be near the lower end of that range. On the bottom line, our outlook for 2018 adjusted earnings per share has improved by $0.15 per share to a range of between $9.70 and $9.90 up from our previous outlook of between $9.55 $9.75 Revised range represents adjusted EPS growth of between 15.5% 17.9%. The increase in our adjusted earnings per share guidance is primarily due to improvements in our outlook for foreign currency, including the modest FX upside realized in the Q1. On a GAAP basis, we have now included the estimated impact of the 2018 footprint realignment program. Accordingly, the GAAP EPS range has been revised to $5.45 to $5.55 versus $7.10 to $7.20 previously.
To summarize, Teleflex is off to a good start in 2018. 1st quarter revenue and adjusted EPS were favorable versus our expectations. Margin expansion was in line with expectations and the integrations of NeoTract and VASCO Solutions remain on schedule. Lastly, we look forward to sharing our longer term strategy and financial outlook for the investment community at our Analyst Day event, which will take place next week on May 11 in New York City. And that concludes my prepared remarks.
Now I'd like to turn the call back over to the operator for Q and A. Operator?
Thank Our first question comes from Isaac Ro with Goldman Sachs. You may begin.
Hey, good morning. Thanks for taking the question. So just on UroLift, hoping you could put a little more detail on the magnitude of investment you're putting into channel? I think you gave us a little bit there, but would appreciate in dollar terms how we should think through the next 12 months to 24 months?
So, I think that as we see NeoTract perform exceptionally well, modestly ahead of our internal expectations. We see the opportunity to solidify the out years growth. So our original plan, as you know, was to go from 50 in 2016 to 70 in 2017. We went above that in 2017 and we were expecting a similar cadence. We think that we will add in the region of 5 to 7 additional salespeople in this year, even above our original plan to continue to accelerate the growth.
The product is doing exceptionally well, I got to say. I spent a day in the field in the last 2 weeks viewing some cases myself. And to see the impact on patients is quite significant. And to see how enthusiastic urologists are to use this product, it also had a fairly impact on me to see that. So a lot of enthusiasm and we're looking forward to having 2 urologists at our Investor Day that are actually going speak specifically to the UroLift on that day.
Got it. And just a follow-up on the Freeze Guide plasma. Could you maybe remind us how you think about size of the opportunity and what the margin impact would be once you get that business up at scale? Thank you.
Yes. So we think that the overall market for freeze dried plasma is approximately $100,000,000 About a quarter of that is in the military and we'll obviously begin in the military segment given that they have helped us to develop this product in doing the clinical studies. As I said in my prepared remarks, we now believe that the product will be ready for submission We anticipate to get our piece done and get it submitted. The margins we haven't quantified yet. We're still in discussions with the military as to what the price
Operator, I think we can take the next question.
Our next question comes from Larry Keusch with Raymond James. You may begin.
Hi, good morning everyone. Liam, just to continue on with UroLift, you also talked about accelerating or I should say investing additional dollars for Asia approval. So could you walk us through a little bit what countries you're thinking there and sort of timelines to get there?
Thanks, Larry, and good morning. Yes, so as you know, we've already submitted for Japan, and that's already within our sphere. We have a direct channel within Australia, which is also within our APAC region. The new regions that we're looking at, we're looking to accelerate our registrations in China, Singapore and in Taiwan. So we think that there are nice significant market opportunities there, and we would like to get the product registered earlier than our original expectations.
Now in some of these areas, it will take a longer period of time. So Singapore and Hong Kong will be fairly quick. Larry, we should get registrations by the end of the year for those. The other geographies will take anything from 1 to 2 years. One thing we're working with the CFDA is to investigate whether we can use the U.
S. Clinical data for the submission. And that's why we're trying to accelerate this process to get a clearer understanding as to whether we will need a Chinese clinical study or whether we can use the U. S. Data.
Okay, perfect. And just on that, just to be clear on Japan, what's the thought there for timing? And then I just had 2 other quick
questions. Yes, sure. So we submitted to the normal timing for to get the shown in registration is in the region of about 18 months. And then it will take 12 to 18 months to get the reimbursement thereafter. So that's the normal time line we would expect, Larry.
As we get updates, we'll keep the investment community informed.
Okay, perfect. And then two other quick ones for you, maybe for Tom. If you could just talk about the revised gating on your spending since it sounds like you had a little bit of an underspend in the 1Q? And then, I guess back to Liam on the distributor restocking, you indicated that you had anticipated that to normalize in the first half. So I'm just wondering how to think about the activity in the Q1 and what that may mean for the 2Q and also if you could speak to any flu benefit in this quarter?
Thank you.
So I'll take the second question first, Tom, if you don't mind. So I'm glad to report, Larry, that we did see the restocking. We got from the big three about a $83,000,000 pickup. And as you know, it was about a $3,800,000 destocking in the prior quarter. And you could see that in particular in the growth rates within our anesthesia and respiratory business.
The respiratory business grew by 3.6% and the anesthesia business grew by 4.9%. So we did see the rebound in those two businesses and we also saw the restocking from distributors to the tune of about $3,000,000 And unfortunately, we see this from time to time with distributors buying patterns outside of our control. And again, we normally see it come back. We did see a good strong flu season, Larry, and that I think is probably reflected in the growth of those businesses as well as the growth within our vascular business, which grew by 6.9%. So all in all, I've got to say I'm really happy with the Q1 and the results that we achieved from our core businesses, the contributions of BSI, the contributions of NeoTract.
And I think we're off to a real solid start for the year. Tom?
And then on the re phasing, as mentioned in the Q1, part of the upside was due to just better expense management, part of it was due to moving some spend out into subsequent quarters. And really the rationale was as these new opportunities to invest behind Replas and NeoTract were emerging, We wanted to see how Q1 turned out to see how much we could afford to pull in and move forward. And thankfully, the Q1 results turned out pretty good. And so, as you look at the balance of the year, you shouldn't assume there's any 1 quarter where the bolus of that spend is. In fact, it's a couple of $1,000,000 that's actually being moved out.
And part of the upside in OpEx in the Q1 will be used to fund some of these additional investments. But as mentioned, in the aggregate, we still expect to spend the same full year amount that was in the plan and then a little bit more given these investments that we've spoken about. So hopefully that helps. I wouldn't expect it to be a large increase in any one given quarter.
Thank you. Our next question comes from David Lewis with Morgan Stanley. You may begin.
Hi, good morning. This is Jay Chadda in for David. Congrats on the quarter. Thank you. Organic growth for questions sequentially was encouraging.
Can you talk about how you see the outlook from here?
Yes. I think we expect to see an accelerating growth organically for our business. I mean, our constant currency guidance is 5% to 5.5%. Our constant currency days adjusted for the quarter was 3.1%. Within the 3.1%, we saw solid volume, good new product revenue, good pricing.
So I'm really, as I said earlier, pleased with the results. And again, our pro form a revenue growth in the quarter was 6.6% days adjusted. So now to get to our 5% to 5.5%, from quarter 2 onwards, we will have a full quarter of VSI growth in our organic growth. In the second half of the year, we will largely anniversary the surgical exit. And in quarter 4, as well as an extra billing day, NeoTract rolls off being counted as organic.
And we'll add, as we said before, 0.5% to our full year revenue. So you should continue to see an increase ratably over the remainder of the year.
Got it. Very clear. Thank you. And then a quick follow-up. VSI also recovered this quarter.
Can you talk about the recovery you saw and any underlying momentum you're seeing in the business in addition to the benefit from DCD conversions?
Yes. So you would see that in our positive pricing. So we were very pleased with the results from our dealer to direct. We've executed very well on that and our European team should get great credit for that. I've got to say, I was really pleased to see BSI come with a double digit days adjusted growth rate, came in at 10%.
And I would also expect that now as we begin to execute on the Go Direct that we should see a modest improvement in BSI over the remainder of the year also.
Thank you.
Thank you. Our next question comes from Richard Newitter with Leerink Partners. You may begin.
Hi, thanks for taking the questions. I have a couple. Maybe just on the restructuring, can you give us any sense as to the cadence of that $25,000,000 to $30,000,000 in pretax annual savings? When do you think we'll start to see that factoring into the P and L? And I know through 2024 is the time period, but that's a long window.
When will we start to see the kind of lion's share of that benefit? And on that, can you just maybe remind us on what's left on your existing restructuring? Thanks.
So I'll ask Tom to go over that if you don't mind, Rich.
Yes. So and we'll go into this in more detail next week in Analyst Day, but it is a long lived project and you shouldn't expect to see the lion's share until kind of the early 2020s is when we'll start to see meaningful savings. So there are some steps that have to be taken first and that's the reason for the lengthy timeline. As for the other restriction programs that are still outstanding, we had disclosed a total of $76,000,000 to $90,000,000 outstanding and I would say that about half of that had been realized by the end of 2017. So there's still meaningful savings out there on the existing programs and the majority of that saving will be realized over the next couple of years, 2018, 2019 2020.
Okay. Thanks. That's helpful. And then just going back to UroLift, very strong quarter for NeoTract again, and I appreciate some of the investments coming up. But you have a competitor that just recently got acquired by a large medtech player And I'm just curious about your thoughts on that technology as it kind of moves into the hands again of a company with bigger resources and clearly make an investment on the category.
How does the increased investment potentially factor into kind of that move, if at all? How do you see the market playing out? And any comparisons between the two technologies would be helpful. Thank you.
So Rich, yes, obviously, we're aware of the acquisitions next year by our competitor. I think what's probably underappreciated by about Teleflex is the amount of sales force that we actually have globally within that urology call point. So Teleflex would have in excess a few 100 salespeople calling on that to urologists on a daily basis. And we have a dedicated sales team with the UroLift product, which is also calling predominantly on doctors' offices and ASCs, which is where the product is moving to. 60% of our revenues for NeoTract, which are coming from outside of the hospital area.
That really fits into what healthcare providers are trying to do. Now the BPH is a massive space, which we never thought that we would be in the BPH space on our own. But what we are determined to do is make sure that UroLift is the standard of care. Our view is that the patient outcomes will win out 7 days a week and twice on Sundays. And we feel that we have a much better catheter.
The results are immediate. We don't ablate any tissue. The Nextera product every other technology ablates tissue. If you burn and cause, therefore, naturally enough, you're going to have bleeding or swelling. And also, I mean, a big one for us is and it's borne out by the clinical study I just spoke about, it's borne out by the LIFT study, 0 sexual dysfunction.
If you're actually cutting, you have a risk of sexual dysfunction and the clinical papers will bear that out. So I think that we're really confident in our technology. We never thought we'd be there in our own risk, but by gosh, we want to make sure that we're the number 1 and we are the standard of care and that's our goal.
Okay. Thanks. Maybe just one last follow-up. Liam, you said that of the $3,800,000 of kind of distributor impact from the Q4, you got back about $3,000,000 in the Q1. Does that mean that we should be thinking about just under $1,000,000 coming back hopefully in the Q2?
Yes. Well, it normally comes back, Rich. So I don't see any reason that it wasn't. I mean, it's not a big number on a full year basis, but I would anticipate that we would see lengthy stocking at the end of quarter 2 and into quarter 3. That would be my expectation, yes.
But I'm glad that the boldness of it came back in the Q1 because that's what I expected.
Excellent. Thank you.
Thank you. Our next question comes from Brian Weinstein with William Blair. You may begin.
I wanted to first start with a higher level question related to share gains. In the past, you guys have talked about approximately 125 basis points of growth coming from this source. Maybe you could update us on how this is tracking according to plan and provide some specific areas on where this has worked and maybe a few areas on where it's fallen short?
Thanks. Could you just clarify sorry, the line wasn't that clear, Brian. The 125 basis points coming from?
Share gains?
So share gains in we didn't make any statement about 100 and 35 basis points in share gains. Coming from which segment, Brian?
Yes, we just had in our notes that over kind of your longer term plan, growth you're expecting some level of growth from share gains. Maybe as a more broader question, you could talk about what you're seeing in terms of these gains in specific segments?
Absolutely. So I think that as I said during my prepared remarks, we see share gains in many areas of our business. One that's particularly encouraging for me is the PIC segment. We grew by over 20% in the key North American market in the pig segment and we're very comfortable that we're taking shares there. I think in the interventional segment that grew by 8 percent in the quarter.
We continue to see strength within our Interventional business. In our anesthesia business, we saw a really solid rebound in our anesthesia business, and we continue to do well within our laryngeal mass, within our blades and within our paint pump area of our business. Overseas, within the EMEA business, I think we're doing particularly well in our surgical business in Europe, where we don't have the impact of the exit from that lower margin, lower growth segment. And obviously, within China, as a result of our decision to go direct, we saw 26% growth in the quarter in China and we also saw China in our Asia Pacific in general performed very, very well. So in those there are some broad areas of where we see ourselves can you talk about trends in Latin
America and some of the emerging markets? Could you talk about trends in Latin America and some of the emerging markets? Thanks.
Yes. So I began giving some comments on Asia and we saw a really solid rebound within Asia. The Latin American business traditionally has been a drag for us. We saw it up 3% in the Q1. We do see Latin America rebounding modestly.
So that's encouraging because, quite frankly, it has been a drag over the last 2 years, and we have seen either flat or negative growth over the past couple of years. So as the oil based economies show some improvement as the currency starts to stabilize, we're starting to see some encouraging signs there. And also in the Middle East, we've and Russia, we've seen a modest rebound as well in those emerging segments. So we're quite encouraged by the trends that we see there, Brian.
Thank you.
Thank you. Our next question comes from Dave Turkaly with J. B. Securities. You may begin.
Good morning. Just to follow-up on some of the pick commentary you made. Just curious on that market size today and where you stand, I think when you had a competitor that was public, they were the largest player. I was curious if you're gaining share there still, maybe even against them. And then I know you had some antimicrobial, antithrombogenic products.
I'm curious as to what percent of your mix
those are? Hey, Dave. So of our catheters, over 90% of the catheters that we sell in our CBC area or in our PIC area are coated catheters. And that is because the hospitals realize that an infection will cost them $43,000 to treat that patient and they won't get reimbursed. And secondly, if they end up in the bottom tier from a hospital acquired condition score, they get a lower reimbursement the following year.
So the overall peak market in North America is around $340,000,000 Our share of that will be we would be in the $35,000,000 area, call it, on an annualized basis. So we continue to take share gains there. Your question as to who we're taking it from, I mean, there's 2 main competitors. There's CRBAR that they were and there's AngioDynamics. I think that we are in a really strong position in our coating.
We've got a good, better, best from a tip positioning technology. And I think all in all, we're really happy with our portfolio. We're really happy that we have these unique coatings that differentiates us in the marketplace. We continue to expect to take share gains over a multiyear period because of all of those factors.
Thanks for all that detail. I know there's been a lot of questions on UroLift, but can you just remind us what rep productivity you think it is at scale? And my last one would just be any update on PerkyDance. Thanks a lot.
Well, I think from rep productivity, the one statistic that I love is that it takes a urology consultant rep about 6 to 7 months to get up to $1,000,000 in revenue in the new territory. So I mean, as we add additional reps, of course, we don't have as many virgin territories as we had originally, but we do see productivity improving. If you took our general pool of urology consultants, we're getting about 2,000,000 now on average from each sales rep within that group. And our best reps are up over the $3,000,000 range. I mean, I was actually I said I was out in the field with a rep a couple of weeks ago.
That sales rep did over $3,000,000 last year. And I think that's really, really experienced salesperson and very successful. But the productivity from the reps, we continue to see it grow and we continue to see adoption of the product. And again, 87% growth in the quarter on NeoTract was very, very encouraging for us.
Thank you.
Thank you. Our next question comes from Anthony Petrone with Jefferies. You may begin.
Thanks. Maybe one for Tom, just on earnings guidance. So there's a little bit of an FX benefit. We also have a little bit of restructuring coming in. Obviously, vascular is getting back a little bit in terms of overall growth and then we have NeoTract.
So maybe just the components of earnings guidance, the adjusted earnings guidance going higher where you see the most benefit from all of those drivers? And then I have 2 follow-up product questions. Thanks.
Okay. So as we took a look at our results for the Q1, really as mentioned, the operating results were largely in line with our expectations with a couple of exceptions and those exceptions being favorable foreign exchange environment. The tax rate came in a little bit better in part due to some favorable rates and in part due to the tax windfall. And then we spoke about the OpEx spend, some of that was favorable and some of that was a re phasing. So as we look at the basis of the raise, really how we're thinking about it is initially when we started the year, we thought foreign exchange would be a tailwind of $0.26 and now we expect it to be a tailwind of $0.42 or a $0.16 improvement there.
The tax rate, as mentioned, given the windfall and a little bit better rate, we now expect to be at the lower
end of our range and about
a 50 basis point improvement in taxes is worth, I think, about $0.06 And so you're up a little bit over 0.20 $0 The OpEx really was pacing and so we're not going to see any full year benefit. In fact, we're going to do a little bit of investment above the full year of previous spend rate. So that's how that the upside from tax and windfall gets kind of carved back a little bit and we are dropping through $0.15 So it's really the potential FX as well as tax benefits that are driving the raise.
Well, I'll
stay on this topic for a moment. As we look at the Analyst Day coming up next week, maybe just maybe frame the discussion in terms of the adjusted operating margin outlook. And I guess my real question in there is, there's one variable that's a potential wildcard and that's reclass. So how do you consider now that we have a new restructuring program, new assets within the portfolio, NeoTract Vascular, how do all of those sort of get factored in and in particular without having guidance on replast, is there a scenario analysis that potentially you will run through with and without replast? And then one follow-up product question.
Thanks.
So, on the revenue line, I mean, we'll go into that in more detail at our Analyst Day. It's only a week away. We give details on replas. I mean, we have a few, let me call them, wildcards with potential upside for us in the longer term and reflaz is one of them. Percuvance is another one that has potential there.
So we will give our guidance based on our portfolio, but with some commentary on what might assist us, I think is what you can expect to see at them.
That's helpful. And then last for me would be on NeoTract and NxThera, Boston Scientific taking out that asset. But my understanding is that the reimbursement for NeoTract is quite a bit more favorable than NxThera. So maybe just a recap on the reimbursement and how it stands today. Thanks.
So the situation, I believe, with the reimbursement for that device is that they have a provisional CPT code. The reimbursement rate will not be determined until early in 2019. So therefore, the comparable there is no comparable. I believe a different code has been used in the past And I believe that they will no longer be using that code because the next year device wasn't technically that type of product. So it's hard to make it comparable as to what their reimbursement is versus NeoTract.
But I can tell you that the NeoTract reimbursement is very favorable for the clinicians and very favorable results for the patients. So we'll know more in early 2019. And then, I guess, they will have to go through the process of bringing on all the private payers. Just as a point of reference, that took us 2.5 or 3 years to bring on all the private payers and we're still only up to 200 no, we're up to 240,000,000 lives. We're very encouraged by that.
But it took us 3 years to get to 240,000,000 lives. So I would imagine that Boston will have to follow a similar process than we did to bring on those payers.
Very helpful. Thank you.
Thank you. Our next question comes from Matthew Mishan with KeyBanc. You may begin.
Great. Thank you for squeezing me in. I just want to start with Asia. I think most of my questions have been asked. Do you think you have the product registration runway and the infrastructure in place to the point where you can potentially sustain like double digit growth in that Asia segment moving forward?
I mean, you're about so it's a little over 10% sales and 10% growth would give you about 100 basis points
of organic growth moving forward? So, our long term goals for the Asia Pacific region is to get into the high singleslowdoubledouble digits. I think we've been pretty constant on that. With regard to our structure for registrations, in the APAC region, we have significant resources to assist with our registrations and we always have had. And quite frankly, Matt, you need that to in order to be able to do the registrations because you got to move them into the languages and the CFDA, you got to work with them to find whether you need a clinical study, whether you don't need a clinical study, what the classification of the product is.
And obviously, we continue to make additional investments into China. And we are, this year, making additional investments into Asia in general for the registration of the NeoTract product because we wanted to make sure that we are well positioned to take advantage of that opportunity in the future. And it takes it can take like 1 to 2 years to get registration in China. So we're acting now to be prepared for 2 years' time. We're acting in Japan to be prepared for 2 or so years' time.
We'll obviously Hong Kong, Singapore should be easier, but some of the geographies do take a significant amount of time. And we will be looking then at Latin America in the future to see what our plan is to accelerate the registration there. So one of the things that I think the Teleflex really brought to the table with the acquisition of NeoTract was that global footprint. And as we said at the time of the acquisition, we will be working to leverage our global footprint to expand this technology into new markets and that's exactly what we're doing.
Okay. Thanks, Liam. And then on NeoTract, I'm not sure you guys ever really provided a quarterly cadence of last year's results for it. Could you give us a sense of how it was phased through 1Q through 4Q last year, so that we don't look at, say, the 87% increase this year in the Q1 and ask why you didn't raise the guidance of 40% for the year?
So I can. I mean, if you go from 1Q to 4Q, so I know 4Q at the top of my head was $39,000,000 3Q was about 34,000,000 dollars 2Q was $30,000,000 and 1Q was about $23,000,000 in that ballpark. So basically, you're that's the basis that we're using for the growth year over year. That's where you get your 87%. And the growth rate even over the prior quarter was greater than 8%.
So we've been pretty consistent with the growth rate on the track and we continue to see that.
All right. Thank you very much.
Thank you. Our next question comes from Mike Maxim with Needham and Company. You may begin.
Hi, thanks for fitting me in. Just wanted to start with vascular solutions. You gave the sales number. Can you just remind us what that implied in terms of pro form a growth? And is the distributor conversion impact behind completely behind you now in that business?
Thanks, Mike. So I'll start with the distributor. It's completely behind us. We've executed on all of the distributor go direct in Europe. And as I said in my prepared remarks, the growth rate was just over 10%.
So again, we're very encouraged by the overall growth rate and it was it grew sequentially over quarter 4. So all of the metrics for BSI are very encouraging for us and we're really enthusiastic about that asset.
Okay, thanks. And then, Tom, just curious on your outlook for commodity costs. I mean, we're seeing oil prices increase and there's talk of tariffs on metals and things like that. So to what degree is that a factor in your cost of goods and at what point would you think that would start to translate into gross margin pressure, if at all?
Well, obviously, we're watching the situation too with the cost of PVC and other components. And we do see some pluses and minuses. Right now, we're not seeing a major impact, a slight uptick in the inputs. Where we're seeing more of an impact is in some labor rates in some of our markets, Mexico and Czech Republic. So we have moved to address compensation levels to the current market.
But right now, the commodities haven't had a significant impact. We'll certainly watch that going forward. Labor has had some impact already.
Okay. And then finally, can you just tell us some selling days for the remainder of the year, whether you're up or down versus prior year? Thanks, pre quarter. Thanks.
Yes. So quarter 2, we've got plus 1. And then obviously, we had one less in quarter 1. And then in quarter 4, we're plus 1 again in quarter 4, Mike.
Okay, great. Thanks a lot.
Thank you. Our next question comes from Matt O'Brien with Piper Jaffray. You may begin.
Thanks for taking the questions. This is Kevin on for Matt today actually. I wanted to jump back to the revenue guidance for the year quickly if we could. I just wanted to discuss why the team didn't choose to take it up slightly on an organic constant currency basis just given the continued NeoTract strength, is the company just being conservative here? And should we be modeling closer to the higher end of that range?
It sounds like the components of that 5% to 5.5% are unchanged with NeoTract providing 50 bps of growth and VSI at 100. So just wanted to talk through that decision process and not bring it up a little bit.
So we feel very comfortable with our guidance range. I mean our constant currency guidance range is 12%, 13%. We took up 1% obviously for the impact of currency. Neotracht is running slightly ahead of our internal expectations after 1 quarter and it is 1 quarter. So we feel very comfortable in our guidance range.
We think our core business had a good solid start to the year at 3.1%. We think that we'll get a full quarter of BSI in quarter 2. We will get an easier comparable in the latter half of the year with the surgical exit. And of course, we've got an extra billing there. But all of that was in our guidance range when we gave it at the beginning of the year.
We anticipated getting a bounce back from the distributors in quarter 1. We anticipated BSI rolling off and all of the other factors. The performance of NeoTract is very encouraging and it's 1 quarter. So we're comfortable in our guidance range of 12% to 13% at the end of the Q1.
Okay. Thanks so much. And then just one more for me. I mean, you guys have been rightsizing the organization and removing some slower growth, large and lower margin businesses, as you said. But there seems to be some larger moving pieces now this year with integrating 2 large acquisitions and the new restructuring program.
So how do you think about that dynamic for managing the portfolio of some of those businesses? Is it going to be decreasing here in 2018 and something that we should look for a little bit later or how do you think about the dynamic?
So with regard to integrating acquisitions, our structure is very beneficial in that regard. So if you look at the 2 acquisitions we're integrating, Vascular Solutions is impacting the interventional business unit. The integration of NeoTract, we set it up as a standalone business unit, so it wouldn't cause disruption within the business. With regard to the restructurings, we have a number of restructuring programs that we've been running through in the last number of years. And the phasing and the timing of this restructuring announcement is timed as a lot of those resources roll off from the existing restructuring programs to give us bandwidth to do further restructuring.
So we do give a lot of thought to the company bandwidth, management bandwidth in our thought process around restructurings and integrations, and we feel that we have sufficient bandwidth to manage all of the projects that we have ongoing at the moment.
Thanks, Liam. That's helpful.
Thank you. Our next question comes from Kristen Stewart with Deutsche Bank. You may begin.
Hi, good morning. Thanks for taking the question. I'm wondering if I missed this, but I think there was a question on Percuvance earlier. I don't know if you guys gave a response to that and where that stands?
So nothing has changed, Kristen. No, we didn't have a question earlier. I'm glad you brought it up actually. So we're currently on path to submit to the FDA in quarter 3 and we are on track to get the product laid in quarter 4. We will do a 100 patient limited market release late in quarter 4 to validate all of the changes that we've made.
So we would expect to see revenue beginning in 2019.
Okay, perfect. And then speaking of 2019, just kind of can you give an update on NeoTract in terms of the accretion? It sounds like just as you had mentioned before, I guess you guys still expect over 40% growth for the year. With the additional investments that you're making, does that change at all the accretion outlook in 2019?
I'll ask Tom to cover that.
Yes. So the investments that we're making really, we don't foresee being an expense burden overall to adversely impact the accretion in 2019. If anything, we should start to benefit from some acceleration in revenue quicker than was previously envisioned given the sales force addition. So you should not expect dilution from these investments,
modeled for the accretion in 2019? Or do you just feel more confident in reaching those goals? I think it was like $0.35 to 0.40 dollars or something like that.
Well, I think as we get closer to 2019, we'll take the opportunity to provide guidance for 2019. We'll want to see obviously how this year plays out. We're clearly off to a good start in the Q1. Revenues have come in well. And that's afforded us some opportunity to kind of move some investments around.
But before commenting specifically on 2019 guidance, we'd like to get a little bit further through this year and the progression of growth this year.
Okay, perfect. Thanks again for taking my questions.
Thank you. Thank you.
Thank you. Our next question is a follow-up from Larry Keusch with Raymond James. You may begin.
Tom, I just want to pick your brain for a moment again on capital allocation and I guess this is also in part for Liam. Just given the integration efforts that you have ongoing right now with Vascular Solutions and NeoTract, what's your ability or comfort to do some additional M and A and also with your leverage ratio around 3.4x? I guess, Tom, again, the question there is, what do you think is a comfortable level for the company in this environment, giving rising rates, etcetera?
So I'll talk broadly and then I'll pass it to Tom. So as I said previously, Larry, our goal this year will be to delever. We are anticipating getting our leverage rate down to below 3x by the end of the year. We would like to get down below 3x leverage. But as we all know, acquisitions are opportunistic.
And as I've said many times, I didn't think that when we did VidaCare in 2013, it would be 2017 before we would do something like vascular solutions. And I didn't think when we did vascular solutions that within before the year was out, we'd be doing NeoTract. So that it is opportunistic. So our goal is to delever. But having said that, it's an opportunistic and very attractive acquisition that was clearly within our we'd have a long hard look at it.
Yes. So I think I'd agree with Liam's sentiments as he's outlined and certainly we'll have to incorporate the current rate environment into our financial analysis to see if any of these acquisitions meet our financial criteria as well as our strategic criteria. But I wouldn't necessarily say that the rising rate environment would take us out of the marketplace.
Okay, terrific. Thanks guys. See you next week.
Thanks, guys.
Thank you. This concludes the question and answer session. I would now like to turn the conference back over to Jake Elguis for closing remarks.
Thanks, operator, and thanks to everyone for joining the call today. This concludes the Teleflex Incorporated Q1 2018 earnings conference call. Have a nice day.
Ladies and gentlemen, this concludes today's conference. Thank you for your participation and have a wonderful day.